BioSpace News Archive

Centene Corporation announced that it has convened a group of medical, non-profit and community leaders to form the Centene Health Disparities Task Force.

Biogen Inc. (Nasdaq: BIIB) today announced additional data from the SPINRAZA (nusinersen) clinical development program that further demonstrate the sustained efficacy and longer-term safety of SPINRAZA in a broad range of patients with spinal muscular atrophy (SMA)

Graybug Vision, Inc., a clinical stage biopharmaceutical company focused on developing transformative medicines to treat vision-threatening diseases of the retina and optic nerve, appoints Parisa Zamiri M.D., Ph.D. as the company’s Chief Medical Officer, effective June 1, 2020.

- Data spotlights NURTEC as the first and only CGRP-targeting agent using a quick-dissolve ODT technology for fast onset of action, return to normal function within one hour and sustained efficacy for 48 hours after a single dose - Release of multiple new data analyses include NURTEC efficacy in triptan-experienced patients, concomitant use with anti-CGRP monoclonal antibodies, patient preference and satisfaction, and improvement in absenteeism, presenteeism, and productivity

Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced a poster presentation as part of the 2020 American Academy of Neurology Science Highlights virtual platform. The presentation will include baseline demographics as well as preliminary pharmacokinetic and biomarker data from the TOPAZ

Sub-distributor has network of state and local government clients seeking testing solutions Return to Church program being initiated in Orlando, Fla. area REHOVOT, Israel, SINGAPORE and NEW YORK, May 18, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Todos Medical Ltd. (OTCQB: TOMDF) , an in vitro diagnostics company focused on the distribution of a comprehensive suite of solutions for the screening and diagnosis of COVID-19 and the development of blood tests for the early detection of

Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that Christian S. Schade, President and Chief Executive Officer, and Eyal C. Attar, Senior Vice President and Chief Medical Officer, will participate in a fireside discussion at the 2020 RBC Capital Markets Global Healthcare Conference on Wednesday,

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the Benchmark Company Healthcare House Call Virtual Video 1x1 Investor Conference, June 15-16, 2020. Raj Mehra, Ph.D., Chairman and CEO, will host meetings via conference calls. For additional information about the Benchmark Co

Conatus Pharmaceuticals Inc. announced that Institutional Shareholder Services Inc. and Glass Lewis, have recommended that Conatus stockholders vote “FOR” Conatus’ proposed merger with Histogen Inc. and “FOR” Conatus’ proposed reverse stock split, both of which are to be considered at Conatus’ upcoming special meeting of stockholders to be held on May 21, 2020.

MagnaCare today announced a collaboration with BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), to bring COVID-19 antibody testing to their Labor clients in the New York metropolitan area. Through this collaborati